aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
aTyr Pharma (Nasdaq: ATYR) announced that Sanjay S. Shukla, M.D., M.S., President and CEO, will present at the Piper Sandler 37th Annual Healthcare Conference in New York, December 2–4, 2025.
The presentation is scheduled for Tuesday, December 2, 2025 at 1:00 PM EST in a fireside chat format. Management will be available for one-on-one investor meetings for registered attendees. A live webcast will be available on the company’s Investor section and a replay will remain on the aTyr website for at least 90 days. For investor inquiries, contact investorrelations@atyrpharma.com.
Positive
- None.
Negative
- None.
News Market Reaction – ATYR
On the day this news was published, ATYR declined 3.29%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Piper Sandler 37th Annual Healthcare Conference, which is scheduled to take place December 2 – 4, 2025, in New York, NY.
Details of the presentation appears below:
Conference: Piper Sandler 37th Annual Healthcare Conference
Date: Tuesday, December 2, 2025
Time: 1:00pm EST
Location: New York, NY
Format: Fireside Chat
In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the event will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the event, a replay of the presentation will be available on the aTyr website for at least 90 days. For more information, contact investorrelations@atyrpharma.com.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
| Contact: |
| Ashlee Dunston |
| Sr. Director, Investor Relations and Public Affairs |
| adunston@atyrpharma.com |
FAQ
When will aTyr Pharma (ATYR) present at the Piper Sandler 37th Annual Healthcare Conference?
Who will represent aTyr Pharma (ATYR) at the Piper Sandler conference?
How can investors watch the aTyr Pharma (ATYR) presentation if they can't attend?
Can investors request one-on-one meetings with aTyr Pharma (ATYR) management at the conference?
Where will the aTyr Pharma (ATYR) Piper Sandler conference presentation take place?
Who should investors contact for more information about aTyr Pharma (ATYR) investor events?
